Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Biogen Inc. Receives Multiple Analyst Downgrades, Shares Fall

December 25, 2024
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has recently faced multiple analyst downgrades, leading to a decline in its stock price. The company, known for its ground-breaking treatments for neurological diseases, saw its shares fall by 5% following the downgrades.

Several analysts expressed concerns about the lack of near-term catalysts for the company. BMO Capital Markets downgraded its rating on Biogen and Merck, stating that there are no significant upcoming catalysts that could propel the stock price higher.

Despite the downgrades, some institutional investors remain optimistic about Biogen's future. Principal Financial Group Inc. recently purchased additional shares of Biogen, indicating their confidence in the company's long-term prospects.

Biogen's earnings report also failed to impress the market, contributing to the decline in its stock price. While the company's revenues met expectations, its earnings per share fell short of analysts' estimates.

Investors are now eagerly awaiting the release of Biogen's pipeline updates, which could be a potential catalyst for a rebound in the stock price. These updates are expected to shed light on the progress of the company's experimental drugs, including its Alzheimer's disease treatment, which is currently in late-stage development.

For a more accurate forecast of Biogen's stock movement, investors are recommended to consult professionals in Stocks Prognosis. Their expertise and insights can help investors make informed decisions regarding the future performance of Biogen's shares.
If you want to leave a comment, then you need Login or Register





Other data for BIIB

Related data

BIIBSeptember 11, 2025Biogen Inc. Stock Price Target Forecast Achieved with 12.88% Profit  ~1 min.

Biogen Inc. (BIIB) investors celebrated as the stock hit the long forecasted price target of 148.84 $ on September 11, 2025, marking a profitable outcome of 12....


BIIBSeptember 11, 2025Biogen Inc. Hits Price Target Forecast with 14.68% Profit  ~1 min.

Amidst recent market volatility, Biogen Inc. has successfully achieved the price target forecast set by QuantWave, resulting in a substantial profit of 14.68%....


BIIBSeptember 11, 2025QuantWave Achieves 14.18% Profit on Biogen Inc. Stock Price Target Forecast  ~1 min.

QuantWave, the automated forecasting platform, successfully reached a price target forecast for Biogen Inc., resulting in a profitable return of 14.18%....


BIIBSeptember 11, 2025Biogen Inc. Stock Price Reaches Forecast Target with 11.82% Profit - QuantWave Success  ~2 min.

Biogen Inc. (NASDAQ: BIIB) has successfully achieved the price target forecast set by QuantWave, resulting in a profit of 11.82%. The forecast signal was issued on July 14, 2025, with a price of $133....


BIIBSeptember 11, 2025Biogen Inc. Stock Hits Price Target Forecast on QuantWave, Generating 9.98% Profit  ~1 min.

Biogen Inc. investors rejoice as the stock hits the price target forecast set by QuantWave, yielding a profitable return of 9.98%. The forecast signal was initiated on July 10, 2025, with a price of $135....


BIIBSeptember 11, 2025Biogen Inc. Stock Hits Price Target Forecast with 13.92% Profit Gain  ~1 min.

Biogen Inc. has achieved the price target forecast set by QuantWave, signaling a long position on June 13th when the stock was at 130.65 $. The target price of 148....


BIIBSeptember 9, 2025Biogen Inc. Stock Forecast Hits Target with 9.58% Profit - QuantWave Achieves Success in Predictive Analytics  ~1 min.

Biogen Inc. stock has recently achieved a significant price target forecast, as predicted by QuantWave's automated forecasting platform. The forecast signal was given on June 16, 2025, with a price of $131....


BIIBSeptember 9, 2025Biogen Inc. Stock Hits Price Target Forecast, Generating 10.35% Profit for Investors  ~1 min.

Biogen Inc. has successfully achieved the price target forecast set by QuantWave, indicating a profitable opportunity for investors who followed the prediction....


BIIBSeptember 3, 2025Biogen Inc. Stock Hits Price Target Forecast for 11.9% Profit: A Success for QuantWave Analytics  ~1 min.

Biogen Inc. stock recently achieved a price target forecast set by QuantWave, resulting in a profit of 11.9%. The forecast signal was given on June 17, 2025, with the stock priced at $126....


BIIBAugust 24, 2025AIA Group Ltd Makes New 663000 Investment in Biogen Inc. NASDAQ:BIIB  ~1 min.

AIA Group Ltd has recently made a significant investment in Biogen Inc., acquiring 663000 shares on the NASDAQ....


BIIBJanuary 1, 2025Biogen Inc. BIIB: Revolutionary Drug Breakthroughs Position Company for Success in 2025  ~2 min.

Biogen Inc., the leading biotechnology company, is making waves in the healthcare industry with their groundbreaking drug innovations....


VRTXJanuary 14, 2025Vertex Pharmaceuticals Inc. Faces Setbacks in Clinical Trials, Resulting in Stock Slide  ~2 min.

Vertex Pharmaceuticals Inc....


AZNMarch 16, 2025AstraZeneca's Experimental Blood Pressure Drug Could Become a Blockbuster  ~2 min.

AstraZeneca PLC (NASDAQ:AZN) has recently developed an experimental drug for treating high blood pressure, which experts believe has a strong potential to become a blockbuster in the pharmaceutical market....


AZNJanuary 2, 2025Groundbreaking Discovery by AstraZeneca Leads to Promising New Cancer Treatment  ~2 min.

AstraZeneca PLC (AZN) has made a groundbreaking discovery in the field of cancer treatment, offering hope to millions of patients around the world....


JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....